Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus

Davies, M. and Speight, J. 2012, Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus, Diabetes, obesity and metabolism, vol. 14, no. 10, pp. 882-892, doi: 10.1111/j.1463-1326.2012.01595.x.

Attached Files
Name Description MIMEType Size Downloads

Title Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus
Author(s) Davies, M.
Speight, J.ORCID iD for Speight, J.
Journal name Diabetes, obesity and metabolism
Volume number 14
Issue number 10
Start page 882
End page 892
Total pages 11
Publisher Wiley - Blackwell Publishing
Place of publication Oxford, England
Publication date 2012
ISSN 1462-8902
Keyword(s) incretin
patient-reported outcome
type 2 diabetes mellitus
treatment satisfaction
Summary Incretin-based therapies have a glucose-dependent mode of action that results in excellent glucose-lowering efficacy with very low risk of hypoglycaemia, and weight neutrality [dipeptidyl peptidase-4 (DPP-4) inhibitors] or weight loss [glucagon-like peptide-1 (GLP-1) receptor agonists], in people with type 2 diabetes mellitus (T2DM). Patient-reported outcomes (PROs) complement physician evaluations of efficacy and tolerability and offer insights into the subjective experience of using modern diabetes treatments. We conducted a systematic search of clinical trials of the GLP-1 receptor agonists liraglutide, exenatide and long-acting exenatide, one of which included the oral DPP-4 inhibitor sitagliptin as a comparator. No other PRO data for DPP-4 inhibitors were identified. This review summarizes PRO data from eight clinical trials, the majority of which used the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and/or Impact of Weight on Quality of Life-Lite (IWQOL-Lite) to evaluate patient experience. People with T2DM were highly satisfied with modern incretin-based therapies compared with traditional therapies. Treatment satisfaction (including perceptions of convenience and flexibility) was high and generally higher with GLP-1 agonists in association with their greater glucose-lowering efficacy and tendency to facilitate weight loss. Weight-related quality of life (QoL) also improved in people using incretin therapies. The glycaemic improvements achieved with GLP-1 receptor agonists, coupled with the low incidence of hypoglycaemia and ability to cause weight loss, seemed to offset potential concern about injections. It is plausible that superior patient-reported benefits found in clinical trials may translate into improved, clinically meaningful, long-term outcomes through increased treatment acceptability. Long-term, prospective data are needed to ascertain whether this is the case in practice.
Language eng
DOI 10.1111/j.1463-1326.2012.01595.x
Field of Research 170106 Health, Clinical and Counselling Psychology
Socio Economic Objective 970117 Expanding Knowledge in Psychology and Cognitive Sciences
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2012, Wiley-Blackwell Publishing
Persistent URL

Document type: Journal Article
Collection: School of Psychology
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 31 times in TR Web of Science
Scopus Citation Count Cited 31 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 282 Abstract Views, 4 File Downloads  -  Detailed Statistics
Created: Tue, 28 Aug 2012, 15:30:07 EST by Jane Moschetti

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact